Checkpoint blockade in the treatment of breast cancer: current status and future directions

被引:0
|
作者
Lironne Wein
Stephen J Luen
Peter Savas
Roberto Salgado
Sherene Loi
机构
[1] Peter MacCallum Cancer Centre,
[2] Department of Pathology/GZA,undefined
[3] University of Melbourne,undefined
来源
British Journal of Cancer | 2018年 / 119卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
There is now accumulating evidence that the host immune system plays an important role in influencing response to treatment and prognosis in breast cancer. Immunotherapy with immune checkpoint inhibitors is a promising and rapidly growing field of interest in many solid tumours, including breast cancer. Trials to date have largely focused on metastatic triple-negative disease, a genomically unstable subtype of breast cancer that is believed to be the most immunogenic and following the development of treatment resistance, has limited treatment options and a particularly poor prognosis. Both checkpoint inhibitor monotherapy and combinations with chemotherapy are being investigated. In this review, we discuss the current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting. We also propose potential ways of improving responses to checkpoint blockade in breast cancer.
引用
收藏
页码:4 / 11
页数:7
相关论文
共 50 条
  • [1] Checkpoint blockade in the treatment of breast cancer: current status and future directions
    Wein, Lironne
    Luen, Stephen J.
    Savas, Peter
    Salgado, Roberto
    Loi, Sherene
    BRITISH JOURNAL OF CANCER, 2018, 119 (01) : 4 - 11
  • [2] Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions
    Bischoff, Joachim
    BREAST CARE, 2018, 13 (01) : 27 - 31
  • [3] Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy
    McArthur, Heather L.
    Page, David B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 922 - 933
  • [4] Lapatinib: Current status and future directions in breast cancer
    Moy, Beverly
    Goss, Paul E.
    ONCOLOGIST, 2006, 11 (10): : 1047 - 1057
  • [5] Immunotherapy in breast cancer: Current status and future directions
    Basu, Amrita
    Ramamoorthi, Ganesan
    Jia, Yongsheng
    Faughn, Jon
    Wiener, Doris
    Awshah, Sabrina
    Kodumudi, Krithika
    Czerniecki, Brian J.
    IMMUNOTHERAPY OF CANCER, 2019, 143 : 295 - 349
  • [6] Epothilones in breast cancer: current status and future directions
    Atzori, Francesco
    Fornier, Monica
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1299 - 1311
  • [7] Breast cancer chemoprevention: Current status and future directions
    Wickerham, DL
    Tan-Chiu, E
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 253 - 259
  • [8] Breast Cancer Radiogenomics: Current Status and Future Directions
    Grimm, Lars J.
    Mazurowski, Maciej A.
    ACADEMIC RADIOLOGY, 2020, 27 (01) : 39 - 46
  • [9] Breast Cancer in Nepal: Current status and future directions
    Giri, Mohan
    Giri, Mamata
    Thapa, Rabin Jung
    Upreti, Bibhuti
    Pariyar, Bijay
    BIOMEDICAL REPORTS, 2018, 8 (04) : 325 - 329
  • [10] Current status and future directions in the treatment of bone metastases from breast cancer
    Leto, Gaetano
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2019, 46 (10) : 968 - 971